Evidence map›Paper›PMID 41890378›Full record

ArticleJournal of pharmacy & bioallied sciences

Efficacy of Azithromycin 1% in the Clinical Management of Bacterial Conjunctivitis.

Apurva H Suthar

Abstract read
In one paragraph

Article in Journal of pharmacy & bioallied sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Apurva H SutharDepartment of Ophthalmology, GMERS Medical College, Vadnagar, Gujarat, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: To evaluate the clinical efficacy and safety of topical azithromycin 1% ophthalmic preparation in bacterial conjunctivitis. Materials and Methods: A prospective observational study was conducted on 150 patients clinically diagnosed with bacterial conjunctivitis and treated with topical azithromycin 1%. Clinical response and adverse events were assessed during follow-up. Results: High clinical cure rates were observed with minimal adverse effects, indicating good efficacy and tolerability. Conclusion: Topical azithromycin 1% is a safe and effective treatment option for bacterial conjunctivitis in routine clinical practice.

Indexed as

Azithromycinbacterial conjunctivitisclinical cureophthalmic antibiotics

Identifiers

PMID41890378
PMCPMC13016157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.